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Platelet aggregationAbstract One pot synthesis and characterization of new 5-[20-(1H-tetrazol-5-yl)-biphenyl-4-
ylmethyl]-4,5,6,7-tetrahydro-thieno[3,2-c]pyridines (3a–k) using amides (2a–k) were reported. The
prepared 5-[20-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine (3a)
is a bioisostere of 40-(6,7-dihydro-4H-thieno [3,2-c]pyridin-5-ylmethyl)-biphenyl-2-carboxylic acid
(1), having good in vivo antithrombotic activity compared with Clopidogrel. The new tetrazole
derivatives (3a–k) were screened for their in vitro activity as platelet aggregation inhibitors.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.
Open access under CC BY-NC-ND license.1. Introduction
Thienopyridines (4,5,6,7-tetrahydro thieno[3,2-c]pyridines)
and their derivatives are important heterocyclic compounds
that are widely distributed in nature. Many of the compounds
containing tetrahydro thienopyridine skeleton are reported as
antibacterial (Srivastava et al., 2007), non-peptide GPIIb/IIIa
antagonists (Katano et al., 1996), platelet aggregators and
antithrombotic agents (Esanu, 1987). The incorporation of
benzylic or substituted benzylic groups on the nitrogen of
the thienopyridine ring can bring an extensive modiﬁcation
in the biological activities of parent compound. Among the
substitutions occurred at nitrogen of the thienopyridine moi-
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Figure 2 Structure of tetrazole containing thienopyridine
moiety.
514 N.R. Challa et al.ety, the increased effect in the biological activity of the parent
moiety affects the good antithrombotic activity in Ticlopidine
and with more increased activity in Clopidogrel. Later on, the
studies proved that the Prasugrel to be more efﬁcient drug can-
didate than the existing Clopidogrel by making the structural
modiﬁcations to the parent thienopyridine moiety (Hiruyoki
et al., 1994). Hence, different substitutions at nitrogen of the
thienopyridine moiety may bring extensive improvement in
the biological activity of the new chemical entities (NCEs).
Biphenyl tetrazole system is the key structural unit in most
of the sartans, non-peptide antagonists of angiotensin II recep-
tors. Along with their well known antihypertensive activity
(Smith et al., 1996; Dickstein et al., 1998), biphenyl tetrazoles
have also been demonstrated as stimulators of growth hor-
mone release (Smith et al., 1993), metallo protease inhibitors
(Green et al., 2000; Toney et al., 1999), antibiotics (Toney
et al., 1998) and chloride channel blockers (Christophersen
and Dahl, 2000). In this context, biphenyl tetrazoles and its
derivatives have received substantial attention.
Recently, we described the synthesis of 40-(6,7-dihydro-4H-
thieno[3,2-c]pyridin-5-ylmethyl)-biphenyl-2-carboxylic acid
derivatives as promising antithrombotic agents (Nageswar
et al., 2011). As part of our continuous efforts in the synthesis
of new thienopyridine derivatives containing biphenyl system,
we arrived at the synthesis of 40-(6,7-dihydro-4H-thieno[3,2-
c]pyridin-5-ylmethyl)-biphenyl-2-carboxylic acid (1) (Fig. 1)
derivatives. We focused on the biphenyl system to incorporate
a hetero cyclic ring system on second position, i.e. on carbox-
ylic acid position. Among the heterocyclic nucleus, we opted to
introduce tetrazole ring system over the carboxylic acid func-
tion on the biphenyl system as tetrazole is a bioisostere of car-
boxylic acid function. Tetrazoles are the nonclassical isosteres
of carboxylic acids (Christophe et al., 2004; Singh et al., 1980;
Anderson et al., 1990; Bernstein and Vacek, 1987). The term
‘‘nonclassical isosterism’’ derives from the concept that the
functional groups having the similar physicochemical proper-
ties can be interchangeable, while the biological activity of
the initial and the new compounds will be similar. Like carbox-
ylic acids the tetrazoles are ionized in the range of physiologi-
cal pH (7.4) and have a planar structure. And at the same
time the ionized tetrazoles are 10 times more lipophilic than
the corresponding carboxylic acids which will enable to pene-
trate the membranes with greater ease. It was proved that
the tetrazoles were more potent candidates over the carboxylic
acids. For instance, Telmisartan is an antihypertensive agent
having biphenyl system along with carboxylic acid as a func-
tional group in its structure where as Losartan is the ﬁrst series
of biphenyl system containing tetrazole ring in its structure.
Among them, Losartan is more potent than the Telmisartan
for the treatment of hypertension. The introduction of tetra-
zole ring into the molecule of 40-(6,7-dihydro-4H-thieno[3,2-
c]pyridin-5-ylmethyl)-biphenyl-2-carboxylic acid 1 and alsoN
S
HO O
Figure 1 Structure of thienopyridine derivative.some of the derivatives of this substrate might afford the
promising metabolically stable analogs.
Thus we have targeted the synthesis of 5-[20-(1H-tetrazol-5-
yl)-biphenyl-4-ylmethyl]-4,5,6,7-tetrahydro-thieno[3,2-c]pyri-
dine (Fig. 2) derivatives (3a–k). For this strategy, we have cho-
sen compound 1 as the starting material. The compound 1 is
converted into tetrazole via amide transformation. Synthesis
of tetrazole could be easily done using (3 + 2) cycloaddition
of the classical nitrile function with sodium azide. But it suffers
from the draw backs of longer reaction time cycle and substi-
tution on the free tetrazole ring is not possible to the single reg-
ioisomer as it offers both the positions for the substitution on
1,2-positions on tetrazole ring. Tetrazole can also be synthe-
sized from alkyl nitrile using TMS azide and trialkyl tin azides
but it suffers from tedious work up procedures along with
puriﬁcation of the materials using chromatographic techniques
like column chromatography. To overcome all the problems
encountered during the preparation of tetrazole derivatives,
we had developed an improved and facile synthesis of tetrazole
using amide derivatives. Here, we report the synthesis of new
5-[20-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-4,5,6,7-tetrahy-
dro-thieno[3,2-c]pyridine and its analogs.
2. Results and discussion
2.1. Chemistry
The conversion of an acid function of compound 1 into amide
2a–k is effected by PCl5 to afford acid chloride which is in situ
converted into amide 2a by one pot synthesis using appropri-
ate amines (Scheme 1). The obtained amide is collected as pure
material without using any chromatographic puriﬁcation. The
one pot synthesis of a tetrazole nucleus from an amide (2a–k)
could be achieved by using PCl5 to afford iminoyl chloride fol-
lowed by treatment with sodium azide affords tetrazole (3a–k)
ring very easily without any chromatographic puriﬁcations.
The process conditions applied for this conversion are appro-
priate to build 1,5-disubstituted biphenyl tetrazoles from the
corresponding substituted amides. The obtained tetrazole
derivatives showed moderate to good in vitro biological activ-
ities as platelet aggregation inhibitors.
Tetrahydro thienopyridine is the core structural fragment
present in all the tetrazole analogs (3a–k) and is responsible
for the biological activity like Ticlopidine, Clopidogrel and
Prasugrel. In general, thienopyridine skeleton is being metabo-
lized in the body after oral administration to form its active
metabolites which irreversibly binds to the P2Y12 class of
ADP receptors on the platelets, thereby inhibiting the platelet
activation to avoid the aggregation. Hence, thienopyridine
serves as pivotal analogs for the activity for the inhibition of
platelet aggregation.
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Where R=H, phenyl, 2-chloro phenyl,3-chlro phenyl, 4-chloro phenyl,2,3-dichloro phenyl, 3,4-dichloro phenyl,  2-fluoro phenyl, 
4-fluoro phenyl, 2,5-difluoro phenyl, 2,3,4-trifluoro phenyl,
Scheme 1 (a) PCl5, dichloromethane; (b) R-NH2, dichloromethane; (c) PCl5, toluene; (d) NaN3, DMF, water.
Table 1 Physical properties of thienopyridine moiety.
Lipinski’s ﬁlters Compound 2 Compound 3a
Molar mass less than 500 Da 349.00 373.00
LogP less than 5 3.283 3.320
H bond donors less than 5 1 1
H bond acceptors less than 10 2 2
Molar refractivity between 40 and 130 100.415 105.592
Table 2 In vitro potency of compounds 3a–k (n= 6–8
experiments) in the inhibition of ADP induced platelet aggre-
gation in human PRP.
Compound % Of inhibition of platelet aggregation
Vehicle
3a 38 ± 2
3b 38 ± 3
3c 49 ± 1
3d 33 ± 2
3e 55 ± 1
3f 44 ± 2
3g 35 ± 4
3h 45 ± 2
3i 42 ± 1
3j 52 ± 1
3k 56 ± 3
Clopidogrel 39 ± 2
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ﬁrmed by applying the Lipinski’s rule of ﬁve to distinguish
drug like and non-drug like molecules using Lipinski’s ﬁlters.
The physical properties of the compounds 2 and 3a were
derived using bioinformatics software available in the litera-
ture (Lipinski et al., 2001). For this we screened both com-
pounds 2 and 3a using Lipinski’s ﬁlters in order to know the
probability of the drug likeness of the analogs. The results
(Table 1) prompted us to derive the structure activity relation-
ship between the new molecules (3a–k) which boosted us to
screen the biological activity of the tetrazole analogs (3a–k).
Herewith, we report the synthesis and antiplatelet activity of
tetrazole containing derivatives of 40-(6,7-dihydro-4H-thie-
no[3,2-c]pyridin-5-ylmethyl)-biphenyl-2-carboxylic acid using
two one pot procedures by avoiding the intermediate stages
and chromatographic puriﬁcations.
2.2. Antiplatelet activity
Antiplatelet activity for all the new compounds 3a–k was per-
formed in vitro following Born’s turbidimetric methods avail-
able in the literature (Born, 1962). The potency of the new
compounds was estimated and compared with Clopidogrel
and the aggregation was induced by adenosine diphosphate
(ADP; 0.3 mM). The test samples were preincubated with
platelets for 5 min at 37 C. All the test compounds were dis-
solved in DMSO at 300 lg/mL concentration. All the tests
were performed within 3 h after collection of blood. Corre-
sponding solvents were used as blank controls for the corre-
sponding tests. The antiplatelet aggregation potency is
expressed as inhibition (%) which is calculated as follows:
Inhibition% ¼ ðA BÞ=A 100where A and B were the absorbance values of the correspond-
ing blank controls and test samples, respectively.
Among all the compounds 3a–k, compound 3e and 3k
showed signiﬁcant platelet aggregation induced by ADP. It
was observed that substituted tetrazoles showed good anti-
platelet activity over the free tetrazole (3a). Among all the sub-
stitutions occurred on the aryl ring, it was observed that
substitution at the 4th position of the aromatic ring is more
prominent than the substitution at other positions. We
attempted to screen the antiplatelet activity of chloro and ﬂu-
oro substituted series from the examples. It was showed that 4-
chloro derivative 3e to be the prominent antiplatelet aggrega-
tor among the other chloro substituted derivatives. It was also
516 N.R. Challa et al.noticed that 2,3,4-trisubstituted derivative (3k) showed good
antiplatelet activity over the other derivatives (Table 1). Sub-
stitution at the 3rd position of the phenyl ring showed poor
antiplatelet activity (3d) over the other positions. Hence, all
the compounds showed moderate to signiﬁcant antiplatelet
activity compared with Clopidogrel (Table 2).
3. Conclusion
Herewith, we report the synthesis and antiplatelet activity of
new thienopyridines derivatives known as 5-[20-(1H-tetrazol-
5-yl)-biphenyl-4-ylmethyl]-4, 5, 6, 7-tetrahydro-thieno[3,2-
c]pyridines (3a–k). From the results and discussions made
above it may be concluded that:
(1) The trisubstituted derivatives should be used in future
drug designing.
(2) Introduction of other heterocyclic moieties may also
bring improved inhibitory activity.
(3) All the compounds showed moderate to signiﬁcant
platelet aggregation inhibitor activity.
4. Experimental
4.1. General
All solvents used were of commercial grade purchased from a
qualiﬁed vendor. Melting point range reported was uncor-
rected and taken on a Polmon melting apparatus. The FT-
IR spectra were recorded in the solid state as KBr dispersion
using a Perkin–Elmer 1650 FT-IR spectrophotometer. Thin
layer chromatography was performed on Merck precoated sil-
ica-gel 60F254 plates using UV light as visualizing agent.
1H
NMR spectra were recorded on 400 MHz Gemini Varian spec-
trometer using DMSO-d6 as solvent and tetramethylsilane as
an internal standard. The mass spectra were recorded on an
Agilent 6310 Ion Trap. Microanalyses of compounds 3a–k
were performed by Elementar Vario micro-analyzer.
4.2. Synthesis
4.2.1. Synthesis of 40-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-
ylmethyl)-biphenyl-2-carboxylic acid amide (2a)
A mixture of 1 (10.0 g, 0.02 mol) and PCl5 (8.87 g, 0.04 mol)
charged into the round bottom ﬂask (RBF) containing dic-
hlormethane (100 mL), maintained the reaction mass at reﬂux
for 2–3 h under inert atmosphere. Solvent was removed com-
pletely under reduced pressure. Then cooled the reaction mass
to 0–5 C and charged dichlormethane (50 mL) into the reac-
tion mass. Stirred the reaction mass for 10–15 min to get clear
solution. Then passed the ammonia gas into the reaction mass
until the pH of the reaction mass becomes basic (pH should be
9–10) at 0–5 C under nitrogen atmosphere to precipitate out
the compound 2a as thick solid. Then raised the temperature
of the reaction mass to 25–30 C and charged saturated
sodium bicarbonate solution (50 mL) into the reaction mass.
Maintained the stirring for 1–2 h, ﬁltered the resulted solid
material and the wet cake was washed frequently with water
till the pH of the mother liquor becomes neutral. The crudecompound was suspended in diisopropyl ether (100 mL) to
afford the title compound quantitatively.
Yield: 90%; mp: 152 C; FT-IR (cm1, KBr): 1643 (–
C‚O), 2918, (ArH), 3186, 3384 (–NH2). MS (m/e): 349.3
(M+ 1); 1H NMR (400 MHz; CDCl3): 3.03 (t, j= 5.2 Hz;
2H), 3.2 (t, j= 5.2 Hz; 2H), 3.57 (s, 2H), 3.74 (s, 2H), 5.35
(s, NH), 5.79 (s, NH), 6.73, (d, j= 5.2 Hz; 1H), 7.1 (d,
j= 5.2 Hz; 1H), 7.38–7.5 (aromatic, 8H). 13C NMR
(100 MHz, CDCl3): 25.46, 50.70, 53.12, 61.73, 122.56,
125.16, 127.45, 128.75, 129.04, 129.17, 130.34, 130.36, 133.43,
133.87, 134.54, 138.49, 139.19, 139.79 and 171.01.
4.2.2. 40-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-ylmethyl)-
biphenyl-2-carboxylic acid phenyl amide (2b)
Yield: 80%; mp: 165 C; FT-IR (cm1, KBr): 1674 (–
C = O), 2921 (ArH), 3386 (amide –NH); MS (m/e): 425.3
(M+ 1); 1H NMR (400 MHz; CDCl3): 2.92 (t, j= 5.2 Hz;
2H), 3.52 (t, j= 5.2 Hz; 2H), 4.03 (s, 2H), 4.34 (s, 2H),
6.57 (d, j= 5.2, 1H), 6.87 (d, j= 5.2, 1H), 7.05–7.75 (aro-
matic, 13H), 9.79 (s, 1H, NH); 13CNMR (100 MHz, CDCl3):
20.87, 48.04, 48.97, 57.31, 119.17, 122.79, 123.90, 123.97,
124.12, 124.22, 126.44, 126.68, 127.18, 127.42, 127.56,
128.36, 128.88, 130.44, 130.62, 136.52, 138.11, 138.21,
141.12 and 166.94.
4.2.3. 40-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-ylmethyl)-
biphenyl-2-carboxylic acid (2-chloro-phenyl)-amide (2c)
Yield: 76%; mp: 172 C; FT-IR (cm1, KBr): 1728 (–C‚O),
2920 (ArH), 3414 (amide –NH); MS (m/e): 458.9 (M+ 1);
1H NMR (400 MHz; CDCl3): 2.64 (t, j= 5.2 Hz; 2H), 2.68
(t, j= 5.2 Hz; 2H), 3.61 (s, 2H), 3.92 (s, 2H), 6.50 (d,
j= 5.2, 1H), 6.87 (d, j= 5.2, 1H), 7.09–7.79 (aromatic,
12H), 8.2 (s, 1H, NH); 13CNMR (100 MHz, CDCl3): 22.16,
49.20, 50.13, 57.58, 121.42, 124.55, 125.50, 127.53, 128.12,
128.41, 128.98, 129.13, 130.32, 130.52, 131.61, 132.03, 137.32,
138.44, 139.52, 142.12 and 169.52.
4.2.4. 40-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-ylmethyl)-
biphenyl-2-carboxylic acid (3-chloro-phenyl)-amide (2d)
Yield: 72%; mp: 175 C; FT-IR (cm1, KBr): 1658 (–C‚O),
2924 (ArH), 3450 (amide –NH); MS (m/e): 458.9 (M+ 1);
1H NMR (400 MHz; CDCl3): 2.77 (t, j= 0.5.2; 2H), 2.84 (t,
j= 5.2, 2H), 3.55 (s, 2H), 3.75 (s, 2H), 6.65 (d, j= 5.2, 1H),
6.90–7.54 (aromatic, 13H), 7.56 (s, 1H, NH); 13CNMR
(100 MHz, CDCl3): 25.40, 50.52, 53.05, 61.53, 117.64,
119.77, 122.58, 124.31, 125.17, 127.88, 128.76, 129.53, 129.64,
129.71, 130.29, 130.82, 133.38, 133.77, 134.52, 134.95, 138.77,
138.86, 139.52 and 167.04.
4.2.5. 40-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-ylmethyl)-
biphenyl-2-carboxylic acid (4-chloro-phenyl)-amide (2e)
Yield: 80%; mp: 190 C; FT-IR (cm1, KBr): 1680 (–C‚O),
2922 (ArH), 3390 (amide –NH); MS (m/e): 458.9 (M+ 1);
1H NMR (400 MHz; CDCl3): 3.07 (t, j= 0.5.2 Hz; 2H), 3.58
(t, j= 5.2 Hz; 2H), 4.08 (s, 2H), 4.41 (s, 2H), 6.80 (d,
j = 5.2 Hz; 1H), 7.31–7.68 (aromatic, 13H), 7.5 (s, 1H, NH);
13CNMR (100 MHz, CDCl3): 22.18, 49.21, 50.11, 58.11,
121.50, 125.55, 125.62, 127.60, 128.09, 128.39, 128.99, 129.12,
130.36, 130.50, 131.60, 132.04, 137.31, 138.43, 139.11, 141.48
and 168.21.
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biphenyl-2-carboxylic acid (2,3-dichloro-phenyl)-amide (2f)
Yield: 73%; mp: 180 C; FT-IR (cm1, KBr): 1660 (–C‚O),
2921 (ArH), 3433 (amide –NH); MS (m/e): 492.8 (M+ 1);
1H NMR (400 MHz; CDCl3): 2.79 (t, j= 5.2 Hz; 2H), 2.87
(t, j= 5.2 Hz; 2H), 3.55 (s, 2H), 3.75 (s, 2H), 6.56 (d,
j= 5.2 Hz; 1H), 6.87–7.86 (aromatic, 12H), 9.79 (s, 1H,
NH); 13CNMR (100 MHz, CDCl3): 25.52, 5064, 53.12, 61.52,
118.82, 121.32, 122.80, 125.22, 127.30, 129.90, 128.71, 129.52,
130.34, 130.38, 131.01, 132.62, 133.38, 133.70, 134.65, 137.16,
138.65, 138.92, 139.50 and 167.23.
4.2.7. 40-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-ylmethyl)-
biphenyl-2-carboxylic acid (3,4-dichloro-phenyl)-amide (2g)
Yield: 75%; mp: 185 C; FT-IR (cm1, KBr): 1659 (–C‚O),
2978 (ArH), 3418 (amide –NH); MS (m/e): 492.8 (M+ 1);
1H NMR (400 MHz; CDCl3): 2.80 (t, j= 5.2 Hz; 2H), 2.88
(t, j= 0.01, 2H), 3.55 (s, 2H), 3.75 (s, 2H), 6.65 (d, j= 5.2,
1H), 6.88–7.86 (aromatic, 12H), 7.57 (s, 1H, NH); 13CNMR
(100 MHz, CDCl3): 25.46, 50.65, 53.07, 61.64, 118.81,
121.26, 122.79, 125.21, 127.48, 127.99, 128.77, 129.65, 130.34,
130.37, 131.08, 132.63, 133.37, 133.70, 134.62, 137.11, 138.62,
138.82, 139.49, and 167.22.
4.2.8. 40-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-ylmethyl)-
biphenyl-2-carboxylic acid (2-ﬂuoro-phenyl)-amide (2h)
Yield: 65%; mp: 162 C; FT-IR (cm1, KBr): 1652 (–C‚O),
2926 (ArH), 3424(amide –NH); MS (m/e): 442.9 (M+ 1);
1H NMR (400 MHz; CDCl3): 2.74 (t, j= 5.2 Hz; 2H), 2.83
(t, j= 5.2 Hz; 2H), 3.54 (s, 2H), 3.73 (s, 2H), 6.55 (d,
j= 5.2 Hz; 1H), 6.78–8.36 (aromatic, 13H), 7.2 (s, 1H, NH);
13CNMR (100 MHz, CDCl3): 25.41, 50.24, 52.85, 61.67,
114.36, 121.30, 122.65, 124.14, 124.53, 125.26, 126.36, 127.82,
128.72, 129.55, 129.70, 130.49, 130.89, 133.34, 133.78, 135.14,
138.19, 138.59, 139.64, 150.87, 153.29 and 167.31.
4.2.9. 40-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-ylmethyl)-
biphenyl-2-carboxylic acid (4-ﬂuoro-phenyl)-amide (2i)
Yield: 60%; mp: 168 C; FT-IR (cm1, KBr): 1655 (–C‚O),
2924 (ArH), 3420 (amide –NH); MS (m/e): 442.9 (M+ 1);
1H NMR (400 MHz; CDCl3): 2.72 (t, j= 5.2 Hz; 2H), 2.82
(t, j= 5.2 Hz; 2H), 3.55 (s, 2H), 3.75 (s, 2H), 6.62 (d,
j= 5.2, 1H), 6.75–8.12 (aromatic, 13H), 7.3 (s, 1H, NH); 13-
CNMR (100 MHz, CDCl3): 25.44, 50.14, 52.75, 61.77,
113.42, 120.30, 121.65, 123.14, 124.55, 125.12, 125.56, 127.80,
128.12, 129.15, 129.60, 130.52, 130.99, 133.44, 133.88, 135.44,
138.11, 137.59, 138.64, 149.87, 152.29 and 167.31.
4.2.10. 40-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-ylmethyl)-
biphenyl-2-carboxylic acid (2,5-diﬂuoro-phenyl)-amide (2j)
Yield: 62%; mp: 174 C; FT-IR (cm1, KBr): 1664 (–C‚O),
2924 (ArH), 3402 (amide -NH); MS (m/e): 460.9 (M+ 1);
1H NMR (400 MHz; CDCl3): 3.25 (t, j= 5.2 Hz, 2H), 3.44
(t, j= 5.2 Hz; 2H), 4.15 (s, 2H), 4.38 (s, 2H), 6.62 (d,
j= 5.2 Hz; 1H), 6.65 (d, j= 5.2 Hz; 1H), 6.68 (d,
j= 5.2 Hz; 1H), 7.22–7.82 (aromatic, 10H), 8.16 (s, 1H,
NH); 13CNMR (100 MHz, CDCl3): 21.38, 48.55, 49.36,
57.62, 108.48, 110.18, 110.43, 114.70, 114.80, 114.92, 115.01,
124.75, 125.61, 126.50, 128.26, 128.44, 129.29, 129.60, 130.48,
131.02, 131.32, 131.95, 134.85, 138.70, 141.64 and 167.10.4.2.11. 40-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-ylmethyl)-
biphenyl-2-carboxylic acid (2,3,4-triﬂuoro-phenyl)-amide (2k)
Yield: 65%; mp: 182 C; FT-IR (cm1, KBr): 1676 (–C‚O),
2920 (ArH), 3380 (amide –NH); MS (m/e): 478.9 (M+ 1);
1H NMR (400 MHz; CDCl3): 2.91 (t, j= 5.2 Hz; 2H), 3.50
(t, j= 5.2 Hz; 2H), 4.11 (s, 2H), 4.36 (s, 2H), 6.55 (d,
j= 5.2 Hz; 1H), 6.80–7.78 (aromatic, 11H), 9.79 (s, 1H,
NH); 13CNMR (100 MHz, CDCl3): 21.52, 48.78, 49.50,
56.62, 107.42, 111.02, 111.53, 113.62, 114.12, 114.96, 115.12,
124.81, 125.12, 126.14, 128.56, 128.78, 129.42, 129.64, 130.52,
131.63, 131.82, 131.98, 133.52, 137.45, 140.52 and 166.12.
4.2.12. Synthesis of 5-[20-(1H-tetrazol-5-yl)-biphenyl-4-
ylmethyl]-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine (3a)
A mixture of amide 2a derivative (8 g, 0.02 mol) and toluene
(96 mL) reﬂuxed for 30–40 minutes using dean stark apparatus
to remove the moisture content in the reaction mass (limit:
water content should not be more than 0.1%w/v) and removed
two volumes (16 mL) of toluene during the reﬂux. Cooled the
reaction mixture to 0–5 C and charged PCl5 (7.0 g; 0.03 mol)
into the reaction mass under nitrogen atmosphere. Raised the
temperature to 50–60 C and maintained for 2–3 h, then sol-
vent was removed under reduced pressure. Cooled the reaction
mixture to 0–5 C and charged precooled DMF (80 mL) into
the mixture. Stirred the reaction mass for 10–15 min to get
clear solution of iminyl chloride. Then charged DMF
(80 mL) and ﬁnely grinded NaN3 was added into another
RBF. Then added the above iminyl chloride solution into
the reaction mass containing sodium azide slowly over a period
of 30–40 min under nitrogen atmosphere. After completion of
the addition, temperature of the reaction mass raised to 25–
30 C and maintained for 2–3 h. Then cooled the reaction mass
to 0–5 C and added water (80 mL) into the reaction mass
slowly over a period of 30–40 min to precipitate out the com-
pound 56a as a crude solid material during the addition. The
crude material was dissolved in ethyl acetate (30 mL) and
washed the organic layer with water (20 mL). Organic layer
was dried over sodium sulfate and the solvent was largely dis-
tilled off to isolate the solid in diisopropyl ether (10 mL) as an
off white crystalline solid.
Yield: 70%; mp: 165 C; FT-IR (cm1, KBr): 1593 (–
C‚C), 2935 (ArH); MS (m/e): 374.1 (M+ 1); 1H NMR
(400 MHz; DMSO): 2.85 (t, j= 5.2 Hz; 2H, CH2, pyridine
ring), 2.90 (t, j= 5.2 Hz; 2H), 3.55 (s, 2H (–CH2, allylic),
3.77 (s, 2H; –CH2, benzylic), 6.78–7.67 (aromatic, 10H).
13C
NMR (100 MHz, CDCl3): 25.14 (–CH2, pyridine ring), 50.57
(–CH2, allylic pyridine ring), 52.71 (–CH2 pyridine ring),
60.96 (–CH2, benzylic), 123.54, 124.72, 125.82, 128.02,
129.15, 129.22, 130.94, 131.00, 131.16, 133.18, 133.86, 137.33,
138.88, 141.77 and 155.11.
4.2.13. 5-[20-(5-phenyl-tetrazol-1-yl)-biphenyl-4-ylmethyl]-
4,5,6,7-tetrahydro-thieno[3,2-c]pyridine (3b)
Yield: 65%; mp: 158 C; FT-IR (cm1, KBr): 1591 (–C‚C),
2930 (ArH); MS (m/e): 450.4 (M+ 1); 1H NMR (400 MHz;
CDCl3): 2.84 (t, j= 5.2 Hz; 2H (–CH2, pyridine ring)),
2.91(t, j= 5.2 Hz; 2H, –CH2, pyridine ring), 3.60 (s, 2H; –
CH2, allylic), 3.71 (s, 2H; benzylic), 6.21–7.30 (aromatic,
15H). 13C NMR (100 MHz, CDCl3): 25.44 (–CH2, pyridine
ring), 50.66 (–CH2, allylic pyridine ring), 53.13 (–CH2 pyridine
ring), 61.47 (–CH2, benzylic), 122.51, 125.16, 127.12, 127.41,
518 N.R. Challa et al.128.17, 128.66, 129.24, 130.27, 130.26, 130.52, 131.06, 131.31,
131.62, 131.89, 133.37, 133.85, 138.19, 138.61, 141.46 and
154.76.
4.2.14. 5-{20-[1-(2-chloro-phenyl)-1H-tetrazol-5-yl]-biphenyl-
4-ylmethyl}-4,5,6,7-tetra hydrothieno[3,2-c]pyridine (3c)
Yield: 60%; mp: 154 C; FT-IR (cm1, KBr): 1594 (–C‚C),
2924 (ArH), 783 (C–Cl); MS (m/e): 484.1 (M+ 1); 1H NMR
(400 MHz; CDCl3): 2.84 (t, j= 5.2 Hz; 2H (–CH2, pyridine
ring)), 2.91(t, j= 5.2 Hz; 2H (–CH2, pyridine ring), 3.60 (s,
2H; -CH2, allylic), 3.71 (s, 2H; benzylic), 6.21–7.30 (aromatic,
14H). 13C NMR (100 MHz, CDCl3): 25.44 (–CH2, pyridine
ring), 50.66 (–CH2, allylic pyridine ring), 53.13 (–CH2 pyridine
ring), 61.47 (–CH2, benzylic), 122.61, 125.06, 127.10, 127.41,
128.27, 128.61, 129.14, 130.17, 130.26, 130.52, 131.06, 131.31,
131.62, 131.89, 133.37, 133.81, 138.09, 138.61, 141.56 and
155.76.
4.2.15. 5-{20-[1-(3-chloro-phenyl)-1H-tetrazol-5-yl]-biphenyl-
4-ylmethyl}-4,5,6,7-tetra hydrothieno[3,2-c]pyridine (3d)
Yield: 60%, mp: 150 C; FT-IR (cm1, KBr): 1593 (–C‚C),
2926 (ArH), 783 (C–Cl); MS (m/e): 484.5 (M+ 1); 1H NMR
(400 MHz; CDCl3): 2.85 (t, j= 5.2 Hz; 2H (–CH2, pyridine
ring)), 2.90(t, j= 5.2 Hz; 2H (–CH2, pyridine ring), 3.61 (s,
2H; –CH2, allylic), 3.72 (s, 2H; benzylic), 6.22–7.30 (aromatic,
14H). 13C NMR (100 MHz, CDCl3): 25.40 (–CH2, pyridine
ring), 50.56 (–CH2, allylic pyridine ring), 53.22 (–CH2 pyridine
ring), 60.42 (–CH2, benzylic), 121.52, 124.08, 127.12, 127.52,
128.31, 128.53, 129.45, 130.52, 130.45, 130.49, 131.21, 131.35,
131.68, 131.85, 132.37, 133.82, 137.21, 138.52, 140.52 and
156.12.
4.2.16. 5-{20-[1-(4-chloro-phenyl)-1H-tetrazol-5-yl]-biphenyl-
4-ylmethyl}-4,5,6,7-tetra hydrothieno[3,2-c]pyridine (3e)
Yield: 50%; mp: 152 C; FT-IR (cm1, KBr): 1497 (–C‚C),
2922 (ArH), 825 (C–Cl); MS (m/e): 484.5 (M+ 1); 1H
NMR (400 MHz; CDCl3): 2.75 (t, j= 5.2; 2H (–CH2, pyri-
dine ring)), 2.91(t, j= 5.2 Hz; 2H (–CH2, pyridine ring),
3.53 (s, 2H; –CH2, allylic), 3.62 (s, 2H; benzylic), 6.59–
7.80 (aromatic, 14H). 13C NMR (100 MHz, CDCl3): 25.44
(–CH2, pyridine ring), 50.55 (–CH2, allylic pyridine ring),
53.00 (–CH2 pyridine ring), 61.41 (–CH2, benzylic), 122.72,
124.49, 125.05, 127.99, 128.22, 128.98, 129.09, 130.46,
130.27, 131.69, 132.37, 133.35, 133.72, 135.28, 137.56,
138.19, 141.7 and 154.05.
4.2.17. 5-{20-[1-(2,3-dichloro-phenyl)-1H-tetrazol-5-yl]-
biphenyl-4-ylmethyl}-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine
(3f)
Yield: 55%; mp: 148 C; FT-IR (cm1, KBr): 1600 (–C‚C),
2921 (ArH), 789 (C–Cl); MS (m/e): 518.6 (M+ 1); 1H NMR
(400 MHz; CDCl3): 2.82 (t, j= 5.2 Hz; 2H (–CH2, pyridine
ring)), 2.89 (t, j=Hz; 2H (–CH2, pyridine ring), 3.58 (s, 2H;
–CH2, allylic), 3.69 (s, 2H; benzylic), 6.12–7.75 (aromatic,
13H). 13C NMR (100 MHz, CDCl3): 25.44 (-CH2, pyridine
ring), 50.69 (–CH2, allylic pyridine ring), 53.14 (–CH2 pyridine
ring), 61.47 (–CH2, benzylic), 122.44, 122.63, 125.06, 126.41,
127.00, 127.60, 128.55, 129.44, 130.42, 131.53, 131.80, 131.86,
133.15, 133.37, 133.77, 134.25, 137.96, 138.84, 141.49 and
155.74.4.2.18. 5-{20-[1-(3.4-dichloro-phenyl)-1H-tetrazol-5-yl]-
biphenyl-4-ylmethyl}-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine
(3g)
Yield: 60%; mp: 155 C; FT-IR (cm1, KBr): 1612 (–C‚C),
2946 (ArH), 789 (C–Cl); MS (m/e): 518.6 (M+ 1); 1H NMR
(400 MHz; CDCl3): 2.76 (t, j= 5.2 Hz; 2H (–CH2, pyridine
ring)), 2.86 (t, j= 5.2 Hz; 2H (–CH2, pyridine ring), 3.52 (s,
2H; –CH2, allylic), 3.66 (s, 2H; benzylic), 6.46–7.54 (aromatic,
13H). 13C NMR (100 MHz, CDCl3): 25.40 (–CH2, pyridine
ring), 50.63 (–CH2, allylic pyridine ring), 53.05 (–CH2 pyridine
ring), 61.31 (–CH2, benzylic), 122.27, 122.56, 125.06, 125.49,
128.04, 128.22, 128.94, 130.37, 130.44, 131.28, 131.82, 132.97,
133.37, 133.45, 133.76, 137.41, 138.78, 141.71 and 154.18.
4.2.19. 5-{20-[1-(2-ﬂuoro-phenyl)-1H-tetrazol-5-yl]-biphenyl-4-
ylmethyl}-4,5,6,7-tetrahydrothieno[3,2-c]pyridine (3h)
Yield: 62%; mp: 170 C; FT-IR (cm1, KBr): 1508 (–C‚C),
2922 (ArH), 767 (C–F); MS (m/e): 468.4 (M+ 1); 1H NMR
(400 MHz; CDCl3): 2.80 (t, j= 5.2 Hz; 2H (–CH2, pyridine
ring)), 2.90(t, j= 5.2 Hz; 2H (–CH2, pyridine ring), 3.56 (s,
2H; –CH2, allylic), 3.65 (s, 2H; benzylic), 6.47–7.76 (aromatic,
14H). 13C NMR (100 MHz, CDCl3): 25.45 (–CH2, pyridine
ring), 50.57 (–CH2, allylic pyridine ring), 53.08 (–CH2 pyridine
ring), 61.51 (–CH2, benzylic), 116.39, 116.59, 121.95, 122.66,
124.31, 125.09, 127.00, 127.62, 128.15, 129.09, 130.22, 131.44,
133.37, 133.82, 137.78, 138.30, 141.46, 154.11 and 155.58.
4.2.20. 5-{20-[1-(4-ﬂuoro-phenyl)-1H-tetrazol-5-yl]-biphenyl-4-
ylmethyl}-4,5,6,7-tetrahydrothieno[3,2-c]pyridine (3i)
Yield: 65%; mp: 174 C; FT-IR (cm1, KBr): 1511 (–C‚C),
2922 (ArH), 837 (C–F); MS (m/e): 468.6 (M+ 1); 1H NMR
(400 MHz; CDCl3): 2.79 (t, j= 5.2 Hz; 2H (–CH2, pyridine
ring)), 2.91 (t, j= 5.2; 2H (–CH2, pyridine ring), 3.54 (s, 2H;
–CH2, allylic), 3.63 (s, 2H; benzylic), 6.59–7.79 (aromatic,
14H). 13C NMR (100 MHz, CDCl3): 25.52 (–CH2, pyridine
ring), 50.51 (–CH2, allylic pyridine ring), 54.12 (–CH2 pyridine
ring), 62.52 (–CH2, benzylic), 116.33, 117.61, 121.85, 123.58,
123.12, 124.11, 127.12, 127.12, 128.52, 129.12, 131.22, 132.55,
133.44, 133.72, 136.58, 137.52, 141.52, 154.52 and 156.12.
4.2.21. 5-{20-[1-(2,5-diﬂuoro-phenyl)-1H-tetrazol-5-yl]-
biphenyl-4-ylmethyl}-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine
(3j)
Yield: 64%; mp: 177 C; FT-IR (cm1, KBr): 1512 (–C‚C),
2903 (ArH), 873 (C–F); MS (m/e): 486.4 (M+ 1); 1H NMR
(400 MHz; CDCl3): 2.80 (t, j= 5.2 Hz; 2H (–CH2, pyridine
ring)), 2.88 (t, j= 5.2 Hz; 2H (–CH2, pyridine ring), 3.56 (s,
2H; –CH2, allylic), 3.65 (s, 2H; benzylic), 6.11–7.51 (aromatic,
13H). 13C NMR (100 MHz, CDCl3): 25.40 (–CH2, pyridine
ring), 50.62 (–CH2, allylic pyridine ring), 53.12 (–CH2 pyridine
ring), 61.38 (–CH2, benzylic), 114.03, 114.29, 117.10, 117.19,
117.32, 117.40, 117.91, 118.14, 122.19, 122.59, 125.16, 127.82,
128.12, 128.88, 129.10, 130.22, 131.50, 131.70, 155.70, 156.76
and 159.20.
4.2.22. 5-{20-[1-(2,3,4-triﬂuoro-phenyl)-1H-tetrazol-5-yl]-
biphenyl-4-ylmethyl}-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine
(3k)
Yield: 65%; mp: 185 C; FT-IR (cm1, KBr): 1515 (–C‚C),
2900 (ArH), 894 (C–F); MS (m/e): 504.4 (M+ 1); 1H NMR
Synthesis and pharmacological evaluation of 5-[20-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl] 519(400 MHz; CDCl3): 2.83 (t, j= 5.2 Hz; 2H (–CH2, pyridine
ring)), 2.92 (t, j=Hz; 2H (–CH2, pyridine ring), 3.58 (s, 2H;
–CH2, allylic), 3.69 (s, 2H; benzylic), 6.24–7.81 (aromatic,
12H). 13C NMR (100 MHz, CDCl3): 25.50 (–CH2, pyridine
ring), 50.76 (–CH2, allylic pyridine ring), 53.10 (–CH2 pyridine
ring), 53.18 (–CH2, benzylic), 111.79, 111.98, 119.70, 121.01,
122.17, 122.68, 125.16, 127.97, 128.21, 129.23, 130.48, 131.67,
131.87, 133.37, 133.52, 133.74, 13.89, 137.71, 139.19, 141.52
and 155.75.
4.3. In vitro antiplatelet aggregation activity studies
4.3.1. Preparation of platelet rich plasma
The citrated blood was used for the preparation of PRP col-
lected from the healthy human volunteer and mixed with
1.0 mL of 3.8% trisodium citrate and centrifuged at 180g for
10 min. The upper two-third fraction of plasma (PRP) was
transferred to another centrifuge tube leaving behind lower
one-third layer to avoid contamination with WBCs and RBCs.
Platelet poor plasma (PPP) was obtained by the centrifugation
of the remaining sample at 2500g for 10 min.
4.3.2. Aggregometry
The antiplatelet aggregation studies were evaluated by a turbi-
dimetric method based on ADP-induced (2.0 lM, 5 lL) plate-
let aggregation in human PRP. Platelet aggregation was
studied at 37 C using Born’s method in a platelet aggregation
module. A ﬁnal concentration of ADP 2.0 lmol/L was used in
a volume of 5 lL. The new compound 0.05 mL at different
concentrations and normal saline were added to 0.45 mL
PRP, respectively. After 5 min, ADP (2.0 lmol/L, 5 lL) was
given. Maximal change in light transmission was assumed to
represent maximal platelet aggregation. Platelet aggregation
was measured and the maximal deﬂection was obtained after
5 min.
The results were expressed as mean ± SEM and the means
were compared using Student’s t-test, p value is <0.05.
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